Trial · NCT06132035
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
NCT06132035, Phase 1, Recruiting, Caregen Co. Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration. Trials, record NCT06132035. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06132035
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
- NCT number
- NCT06132035
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 45 participants, estimated
- Lead sponsor
- Caregen Co. Ltd.
- Conditions
- Age-related Wet Macular Degeneration
- Interventions
- CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]
- First posted
- 2023-11-15
- Last updated
- 2025-02-07
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The percentage of occurrence of Adverse Events (AE) | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Primary | The number of Adverse Events (AE) that occurs | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Primary | Change in IOP with study drug compared to placebo | Screening, Day 0, Day 28, Day 56 & Day 84 | Mean change in intraocular pressure (IOP) with study drug compared to placebo from baseline to end of study |
| Primary | Change in intraocular inflammation with study drug compared to placebo | Screening, Day 0, Day 28, Day 56 & Day 84 | Mean change in intraocular inflammation with study drug compared to placebo from baseline to end of study |
| Primary | Incidence and severity of ocular and non-ocular adverse events of CG-P5 peptide eye drops and Placebo | Day 0, Day 28, Day 56 & Day 84 | Mean change in incidence and severity of ocular and non-ocular adverse events of CG-P5 peptide eye drops and Placebo with study drug compared to placebo from baseline to end of study |
| Secondary | Change in best corrected visual acuity (BCVA) of study drug compared to Eylea® and placebo as measured by ≥15 Early ETDRS letter score at the end of 84 days | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Change in CNV area on fluorescence angiography with study drug compared to Eylea® and placebo on day 28, day 56 and day 84 | Day 28, Day 56 & Day 84 | |
| Secondary | Mean decrease in central retinal thickness on SD-OCT with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Mean decrease in total macular volume on optical coherence tomography with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 | |
| Secondary | Proportion of patients with change in BCVA with study drug compared to Eylea® and placebo from baseline to end of study | Screening, Day 0, Day 28, Day 56 & Day 84 |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06132035
GET https://conductscience.org/api/trials/v1/NCT06132035/registered?page=2